A new report by visiongain predicts that the Translational Regenerative Medicine market will reach $12.1bn in 2020. This forecast and others appear in Translational Regenerative Medicine: Market Prospects 2016-2026 – Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?, published in January 2016. Visiongain is a business information provider based in London, UK.

The Translational Regenerative Medicine: Market Prospects 2016-2026 report examines the current and future trends in the Translational Regenerative Medicine market.

Translational Regenerative Medicine (TRM) refers to the efforts to ‘translate’ preclinical research on regenerative medicine into clinical therapies – “from bench to bedside”. A great deal of basic research has been performed in the past few decades investigating the therapeutic potential of stem cells, gene replacement and bioengineered tissues. We are now at a point where therapeutic products have reached the market and there are a great number of therapies currently in late-stage clinical trials that have the potential to enter into the market in the next 10 years. The translational regenerative medicine market is set to show very strong growth as a number of therapies in areas of unmet clinical need with the potential to revolutionise the treatment of rare and chronic diseases are set to reach the market in the near future. Given the unmatched therapeutic potential of TRM therapies, understanding the market and the opportunities available is crucial for all those in fields related to the sector.

In this report, we analyse the sales of a wide range of therapeutic products in the following submarkets: Stem Cells, Tissue Engineering and Gene Therapy. Products featured include: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec). Pipeline analysis and clinical trial progress for the most promising therapies in these submarkets are also included for all of the major submarkets. The prospects for the leading national and regional markets, including the US, Europe, Asia-Pacific and Rest of World are also in this report. Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the Translational Regenerative Medicine market. Historical financial performance over 5 years is analysed, along with a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: “One of the major issues that will be faced by healthcare systems around the world in the next 20 to 25 years is an ageing population coupled with an increase in chronic diseases. Translational regenerative medicine is beginning to play an important part in the treatment and management of various chronic conditions and this trend will only continue over the forecast period. The development pipeline for TRM products appears to be strong, with many product candidates beginning to enter late-stage clinical trials. These products have the potential to enter the market during the forecast period and beyond. The prospect of curative treatment in disease areas where there are high levels of unmet medical needs will continue to drive the regenerative medicine market. However the success of this relatively young market in future will require the combined efforts of biotech and pharmaceutical companies as well as support from healthcare payers, regulatory bodies and governments around the world.”
Visiongain’s report provides revenue forecasts to 2026 for the translational regenerative medicine market and its leading products, submarkets and regional markets. The report discusses selected leading companies which hold significant shares of the market. These companies include Alphatec Spine, Anterogen, Athersys, Avita Medical, AxoGen, Medipost, Mesoblast, NuVasive, Ocata Therapeutics, Organogenesis, Osiris Therapeutics, Pharmicell, Regenersys, TiGenix, UniQure and Vericel Corporation. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

The Translational Regenerative Medicine: Market Prospects 2016-2026 – Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?, adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.